Exscientia

Exscientia

Applying artificial intelligence and big data processing to accelerate discovery and development of drugs. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
GBP2020202120222023202420252026
Revenues13.2m20.8m20.6m20.1m30.2m39.8m25.0m
% growth10 %58 %(1 %)(3 %)50 %32 %(37 %)
EBITDA(31.7m)(43.0m)(144m)(144m)(145m)(140m)(165m)
% EBITDA margin(240 %)(207 %)(697 %)(717 %)(479 %)(352 %)(659 %)
Profit(30.4m)(37.3m)(89.8m)(146m)(132m)(138m)-
% profit margin(230 %)(180 %)(436 %)(727 %)(437 %)(347 %)-
EV / revenue-57.8x2.5x19.3x11.2x3.6x-0.3x
EV / EBITDA--27.9x-0.4x-2.7x-2.3x-1.0x0.1x
R&D budget14.9m33.4m97.4m128m---
R&D % of revenue113 %161 %473 %640 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
*

€23.0m

Series B

$70.0m

Series C

$4.2m

Grant

$30.0m

Series C

$525m

Valuation: $1.0b

57.5x EV/LTM Revenues

-23.9x EV/LTM EBITDA

Series D

$1.5m

Grant
N/A

$305m

Valuation: $2.9b

166.7x EV/LTM Revenues

-69.4x EV/LTM EBITDA

IPO

$160m

Private Placement non VC
*

$2.3m

Grant
*

$688m

Valuation: $688m

Acquisition
Total FundingAUD1.0b

Recent News about Exscientia

Edit
More about Exscientiainfo icon
Edit

Exscientia is a technology-driven company specializing in the design and development of drugs using artificial intelligence (AI). The company operates in the pharmaceutical and biotechnology market, focusing on creating more effective medicines at a faster pace. Exscientia serves pharmaceutical companies, research institutions, and healthcare providers by leveraging AI to enhance drug discovery and development processes. The business model revolves around partnerships and collaborations with major pharmaceutical firms, where Exscientia provides its AI-driven solutions to accelerate drug development. Revenue is generated through milestone payments, licensing fees, and royalties from successfully developed drugs.

Keywords: AI, drug design, drug development, pharmaceutical, biotechnology, healthcare, partnerships, licensing, royalties, innovation.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Exscientia

Edit
Kinetic Discovery
ACQUISITION by Exscientia Nov 2018
Allcyte
ACQUISITION by Exscientia Jun 2021